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A surge of discoveries in the 
genetics of disease
he past 4 years have yielded an unparalleled
number of discoveries in the field of the genetics of
human disease. In particular, huge strides have been
made in the discovery of DNA sequence variants that
are associated with risk of common complex diseases,
such as type 2 diabetes, myocardial infarction, Crohn’s
disease, breast cancer, and prostate cancer. Prior to 2006,
in spite of huge efforts by dedicated researchers, only a
few sequence variants had been found to be associated
with these diseases that had been adequately verified by
replication in well-powered studies. By October of 2009,
according to the Catalog of Genome-Wide Association
Studies,
1,2 the number of replicated associations of
sequence variants with these diseases was 44, 10, 59, 14,
and 28, respectively (obtained by counting unique vari-
ants reported as statistically significant in more than one
study, or in at least two population samples from the
same study). Figure 1 shows the total count of replicated
disease associations by year of publication, based on the
same criteria, as reported by this database. These num-
bers will almost certainly continue to rise at a rapid rate. 
This sudden progress is due to the advent of genome-
wide association studies (GWAS), made possible by a
combination of at least four key developments. The first
is the wealth of knowledge that has been produced
about sequence variation in the human genome, in large
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Technological advances in the field of human genetics
have resulted in a wave of discoveries of common DNA
sequence variants that are associated with a risk of com-
mon complex diseases, such as heart attack, that account
for a substantial proportion of morbidity, mortality, and
health care costs in most contemporary populations. The
overall predictive power of these sequence variants can
be considerable, due to the high incidence of these dis-
eases and the sheer number of associations that have
been discovered. Health care providers have been slow
to utilize this knowledge for preventative medicine.
However, several companies have taken on a transla-
tional role by offering genetic tests based on these dis-
coveries direct to consumers. In this paper, we review the
current state and future prospects of such genetic tests,
as scientists involved both in the discovery of disease
associations and the development of genetic tests.
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6 and the ensu-
ing HapMap project.
7The second is the development of
high-throughput microarray genotyping technologies,
that now enable researchers to simultaneously and rel-
atively cheaply assess genotypes at hundreds of thou-
sands of single-nucleotide polymorphisms (SNPs) across
the genome. The third is the availability of collections of
DNA samples from large numbers of individuals who
suffer from the diseases of interest and controls from the
same populations. Another factor that has contributed
to the success of GWAS is the close and fruitful cooper-
ation between research groups and journals in defining
conservative and robust standards for the verification of
disease association signals obtained using this approach. 
The recent discoveries of sequence variants associated
with the risk of complex diseases represent an important
step in the task of understanding their biology, of which
we are still remarkably ignorant. While some of the
newly discovered associations were found in genes
already suspected of playing a role in etiology, most are
in, or close to, genes with no prior connection to the dis-
ease in question. These latter discoveries, in particular,
represent important new points of departure for more
focused research into the biology and etiology of these
diseases. 
While the discovery rate of new disease-associated vari-
ants shows no signs of decline, there is good reason to
believe that much of the lowest-hanging fruit has already
been picked. These are the common sequence variants
that have an easily detected impact on disease risk, given
the existing sample sizes of cases and controls (ie, with an
odds ratio of more than 1.1) and that are covered by the
existing microarray genotyping platforms. Some
researchers argue for continuation of the GWAS
approach, with larger sample sizes to detect more com-
mon variants with small effect.
8 Others argue for a
change of strategy, pointing out that the combined effects
of variants that are likely to be found with more GWAS
only account for a part of the overall heritability of the
diseases concerned.
9 Proposals have been made to pay
greater attention to rare variants, copy number variants,
epigenetic factors, or epistatic effects between unlinked
sequence variants. At least some of these aims will be
achieved in the near future, as further technological
developments make full genome sequencing and more
comprehensive microarray genotyping platforms realis-
tic options for large-scale disease studies. 
Translation of disease association 
findings for public use
Clearly, there is more to be found, and it seems obvious
to us that all of the aforementioned lines of research
should be pursued. However, at the same time as geneti-
cists continue their hunt for new disease-associated
sequence variants and attempt to determine the func-
tional relevance of the variants they have already dis-
covered, they must address an equally pressing issue of
practical concern in relation to existing knowledge. To
date, more than 1000 sequence variants have been dis-
covered with robustly verified disease associations to
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Figure 1. The number of replicated sequence variants associated with dis-
eases and medically relevant traits by publication year of first
report in genome-wide association studies according to the
Catalog of Genome-Wide Association Studies on October 20th
2009. Counts were obtained by counting unique variants
reported as statistically significant (at the level of P< 1.0 x 10-5)
in more than one study or in at least two population samples
from the same study. They represent a total of 1108 replicated
associations to sequence variants based on 132 diseases and
medically relevant traits. Note that in some cases the Catalog of
Genome-Wide Association Studies reports multiple correlated
single-nucleotide polymorphisms (SNPs) from the same genomic
region, and thus the numbers shown are likely to be overesti-
mates. However, the 1108 associated SNPs belong to 871 dif-
ferent genomic regions, and this latter number is likely to be an
underestimate of the overall number of associations discovered.
This is because some regions are known to contain multiple
independent associations to the same trait—for example, region
8q24 and prostate cancer.
3 Also, not all bona fide disease-asso-
ciated sequence variants are included in the catalog, for exam-
ple several that have been reported for age-related macular
degeneration.
4,5
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1These diseases account
for a substantial proportion of morbidity, mortality, and
health care costs in most contemporary populations.
Even though the functional impact of most of these vari-
ants is not yet understood, their association with disease
imbues them with intrinsic value for both the general
public and health care practitioners. This is because the
strength of their association in a population reflects the
degree to which they can be used to improve predictions
of disease risk for individuals. 
Disease risk stratification (by age, sex, weight, and other
biological markers) forms the cornerstone of effective
screening programs. It also serves an important role in
increasing the health awareness of individuals, thereby
promoting the adoption of preventative measures and
leading to earlier diagnosis. The overall result is not only
a healthier population, but a reduction in the burgeon-
ing cost of health care, much of which stems from late
treatment of preventable diseases. It follows that con-
siderable additional health benefit and cost-effectiveness
could be achieved through the addition of recently dis-
covered genetic factors. Although such genetic tests are
available, they have yet to be routinely adopted by major
health care providers. This may be partly due to a lack
of familiarity with such tests, or with their scientific basis,
or due to an inherent resistance that stems from finan-
cial or organizational concerns. However, genetic tests
are also available directly to the public through the
Internet, where they have been positively received
through a combination of health concerns, curiosity, and
recreational interest in genetics and ancestry. 
The authors of this article are members of a research
team at deCODE Genetics that has contributed to the
ongoing wave of discoveries in the genetics of complex
disease and intends to remain at the forefront of this
field in the coming years. However, from 2007 deCODE
Genetics has also been a leader in using this knowledge
to develop tests to evaluate genetic risk, both in the form
of diagnostic products aimed at health care providers,
and a personal genome scan, under the name of
deCODEme, which is sold directly to consumers via the
Internet. In what follows, we will outline the nature of
the genetic tests provided by deCODE Genetics and
others, and the value we believe they can bring by
informing individuals about their health prospects and
motivating them to take preventative measures where
possible or to seek early diagnosis. We will also discuss
some of the concerns raised by such genetic tests.
The nature of the genome and 
possibilities of genetic testing
Before moving on to a description of the kinds of
genetic tests that are currently available to health care
providers and the general public, it may be helpful to
consider the nature of the genome. This can help us to
understand what kind of information the genome can
offer and thereby what kind of genetic tests are possible.
The genome constitutes an extremely complex set of
instructions for the assembly and maintenance of an
organism, within some normal range of environmental
conditions. For humans these instructions are almost
exclusively encoded in the sequence of the roughly 3 bil-
lion nucleotides that make up the genome. 
We may consider a human being as a vast collection of
phenotypic traits, ranging from, for example, height and
skin pigmentation to less perceptible features such as
blood insulin levels or the build-up of amyloid plaques
in brain tissue. All such traits are the outcome of an
interaction between instructions from one or more parts
of the genome and some set of environmental factors.
Most phenotypic traits exhibit some variation among
individuals that reflects underlying differences in DNA
sequence and differences in exposure to environmen-
tal conditions. In some cases, differences between indi-
viduals exposed to normal environmental conditions are
solely due to DNA sequence variants from a single gene.
An example of a trait that is fully determined by
sequence variants, and is inherited in accordance with
simple Mendelian rules of inheritance, is the capacity to
metabolize the amino acid phenylalanine, that when
lacking, results in the disease phenylketonuria. More
often, however, trait variation among individuals can be
traced to many DNA sequence variants and environ-
mental factors. 
The power to correctly predict traits such as the devel-
opment of disease for individuals using a genetic test
(that is, the clinical validity of the test) depends on the
nature of the relationship between genotype and phe-
notype. Many of the key human diseases, the so-called
common complex diseases, are substantially affected by
environmental factors. This means that the predictive
power of genetic tests for these diseases will be less than
for “simple” traits such as phenylketonuria (although the
validity for such tests could be boosted by including
known environmental risk factors). Nonetheless, the
potential health and economic rewards gained from
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numbers of individuals in a population are substantial.
No matter how many sequence variants and environ-
mental factors contribute to a given phenotypic trait, all
other things being equal, the accuracy of prediction is
always increased by the inclusion of just one truly asso-
ciated sequence variant. 
Diseases may be defined as the fraction of variation in
physiological function that lies outside the normal range,
such that either the quality of life is impaired, or the
probability of untimely death is raised to an unacceptable
level. It is no coincidence that diseases are the focus of
most existing genetic tests, because they have been the
primary focus to date of research into genotype-pheno-
type associations in humans. However, once reliable
information has been gathered about an association
between any phenotypic trait and a set of sequence vari-
ants, it becomes possible to develop a genetic test to esti-
mate genetic propensity for that trait. In fact, there are
already several genetic tests on the market that include
nondisease traits such as eye color, male-pattern baldness,
bitter taste perception, and drug metabolism. Such traits
are often ignored by commentators on genetic testing,
but they are likely to play a larger role in this field as our
understanding of the functional impact of sequence vari-
ants on normal human phenotypic variation advances. 
In addition to enabling the assessment of genetic pre-
dispositions to particular phenotypic traits, the genome
holds a record of ancestry and genealogical relationships
between all people. This information is inscribed into the
genome as it is replicated and transmitted from parents
to offspring with a small number of changes in the form
of mutations and recombination events. In the world of
consumer genetic tests, ancestry has been a leading area
of interest, with considerable sales of tests based on the
uniparentally inherited genetic material from mito-
chondria and Y chromosomes.
10
The use of genetic markers to verify the existence of
close family relationships between individuals is a rela-
tively trivial task that is routinely performed in forensic
laboratories and in tests that are already available to the
public. The introduction of microarray genotyping plat-
forms with hundreds of thousands of SNPs is likely to
facilitate the development of more powerful algorithms
to explicitly test for more distant genealogical relation-
ships between individuals. Such data are already used in
genetic tests in conjunction with recently developed sta-
tistical methods from population genetics to provide
detailed assessments of ancestry and admixture. The
results from these analyses are in effect summary analy-
ses of the genealogical relationship of an individual to
different populations from around the world. As the
magnitude of comparative data from such populations
grows and the number of sequence variants assessed
increases (for example, through full genome sequenc-
ing), there will be considerable improvements in the
detail and accuracy of ancestry assessments and
genealogical testing.
Genetic tests of ancestry are typically defined as recre-
ational by commentators, and somehow qualitatively dif-
ferent from tests that evaluate disease risk.
11,12 However,
it is important to bear in mind that in the genome, infor-
mation about function and ancestry is inexorably inter-
twined. Sequence variants that are used in an ancestry
test today, on the basis of having no known function,
may well be found to be associated with a disease or
medically relevant traits tomorrow. Moreover, to the
extent that disease risks vary between populations due
to differing frequencies of the underlying associated
sequence variants, it follows that tests of ancestry are in
effect tests, albeit low-powered tests, of genetic risk of
disease.
The past and present of genetic testing
At present, a wide range of genetic tests are available
either through health care providers or by companies
direct to the consumer (DTC). Indeed, there are now so
many that it is impossible to provide a comprehensive
overview of them all. To begin with, most tests were per-
formed by university or hospital laboratories within the
scope of health care provision. They were based on rare
and highly penetrant sequence variants that are strongly
associated with a particular disease. Included in this cat-
egory are tests used for prenatal and newborn screening,
diagnostic testing for chromosome abnormalities, carrier
testing, and predictive testing for particular conditions
such as Huntington’s disease and hemochromatosis. In
time, companies offering such tests emerged, in some
cases established by people from the aforementioned
universities or hospitals. An early example is the com-
pany Myriad Genetics, that patented and marketed pre-
dictive tests for breast cancer based on variants in the
BRCA genes (that confer a roughly fivefold risk of
developing this disease). 
Translational research
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providers have in common is that the variants tested are
rare and highly penetrant (ie, their clinical validity is
high). Consequently, very few individuals from the gen-
eral population would be expected to receive positive
results from such tests—as is the case, for example, in
population screening for phenylketonuria mutations. In
many cases, however, such tests are provided on the
basis of clinical diagnosis or familial risk, which increases
the fraction of positive results from the tests. For indi-
viduals who receive positive results, the implications
tend to be a very high probability of disease. Thus, test-
takers often meet a genetic counselor prior to tests and
after in light of a positive result (with treatment if applic-
able). The use of tests for rare and highly penetrant
sequence variants is widespread among health care
providers in most countries. Many have also adopted
predictive tests for breast cancer (using variants in the
BRCA gene), and Alzheimer’s disease, based on more
common variants in the APOE gene that confer a four-
fold risk. However, they have been slow or reluctant to
take advantage of the recent wave of robustly replicated
GWAS discoveries of variants associated with increased
disease risk ranging from 1.05-fold to 7-fold. 
In spite of the reluctance of health care providers to
adopt genetic tests for common diseases, a growing num-
ber of companies have been harnessing findings from
GWAS and other genetic studies to design tests that are
sold DTC, mainly through the Internet. Most currently
available DTC tests are based on a handful of sequence
variants and focus on a specific application, such as
ancestry, family relationships, or the testing of genetic
risk for particular diseases. Often a particular company
will offer several such small tests covering one or more
of these areas. On top of this, a few companies are now
offering DTC personal genome scans. These products
are mostly based on large-scale and cost-effective
microarray genotyping platforms that test 500 000 to 1
million SNPs from across the entire genome, but in a few
cases on more expensive full-genome sequencing. The
four best-known providers of DTC personal genome
scans are, in order of appearance on the market,
deCODEme (the product the authors are involved
with), 23 and me, Navigenics, and Knome. Such products
typically provide consumers with estimates of risk or
predispositions to many diseases or traits, in addition to
a range of tests of ancestry and family relationships
through a secure personal Web site account. Aside from
the breadth of tests that such a large number of SNPs
can offer, one advantage of the personal genome scans
for consumers is that they can (at least in principle)
obtain updated estimates for all tests as new discoveries
are made. Thus, the initial purchase of the test may be
viewed as an investment that yields interest in the form
of accumulating knowledge from new discoveries. To
date, the companies providing DTC personal genome
scans have been fairly active in updating the tests
offered on their Web sites. In addition, customers can
download their genotypes onto their own computers and
analyze the data for themselves (for example, by upload-
ing genotypes on Web sites such as SNPedia or seeking
advice on layman Web sites such as DNA-forums.org).
Addressing the concerns of some scientists
about DTC genetic tests
Many of the recent commentaries about DTC genetic
testing in the scientific literature have focused on the
personal genome scans
11-17 and in particular on concerns
about the disease risk estimates they provide to cus-
tomers. These concerns may be divided into two main
themes. 
First, there are questions about the validity of the tests.
The most common criticism here is that because the risk
conferred by each variant used in these tests tends to be
low (odds ratio <2), then the accuracy in predicting risk
of disease for individuals (ie, their clinical validity) will
also be low.
11-13,15,18 Such comments either explicitly or
implicitly compare the new tests with older tests that are
already in use by health care providers in a way that is
highly misleading. If we take a multifactorial disease
such as heart attack, then it is self-evident that one can-
not design a genetic test with predictive power as great
as that for Huntington’s disease, which is rarer, solely
caused by mutations in one gene, and is negligibly
affected by environmental factors. However, it is wrong
to think that the predictive power of genetic tests based
on GWAS findings is insignificant and not clinically rel-
evant. Take, for example, the test for heart attack in the
deCODEme personal genome scan, which includes eight
independent SNPs with strong evidence for association
to this disease
19-23 at the time of writing. This test alone
can allow for the identification of 10% of people of
European decent who have at least 1.4 times greater risk
of developing a heart attack than the average person in
the population. The average relative risk in this group is
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DCNS_44_5.qxd:DCNS#44  10/03/10  1:44  Page 651.6. Since the lifetime risk of suffering a heart attack is
42% for men over the age of 40,
24 it follows that this test
can identify men who have, on average, a lifetime risk of
67% of developing the most lethal disease of man.
25
There is a dramatic difference between 42% and 67%
lifetime risk. For example, individuals who are in the top
quintile of the concentration of LDL cholesterol have
only 1.3 times the population average risk of having a
heart attack. Hence, a genetic test based on recently dis-
covered sequence variants can identify people with
added risk of heart attack that is twice that of those who
are at the top of the cholesterol curve. In this context,
it is important to keep in mind that the ability to assess
risk of the heart attack by measuring serum cholesterol
has transformed cardiology into the most important field
of preventive medicine. Given the rather high lifetime
risk of heart attack in most industrialized populations,
then it follows that even a small increase in predictive
power for each individual can be valuable. 
Comparable estimates of average relative risk in the top
10% of people for other diseases included in the
deCODEme genome scan are, for example, 5.2 for age-
related macular degeneration, 1.8 for type 2 diabetes and
3.0 for Crohn’s disease. There is good reason to believe
that the predictive power of these genetic tests will
increase in the near future. On the one hand, we expect
additional associated sequence variants to be discovered.
On the other hand, because risk estimates in current
tests are typically only stratified by sex and ethnicity,
advances can be made through the inclusion of other rel-
evant background variables (for example, the waist-to-
hip ratio and smoking history in the case of heart
attack). In both cases, further epidemiological research
is needed. However, contrary to the views of some com-
mentators,
11,13 these are not grounds for delay. The value
of the discoveries so far, as reflected in the aforemen-
tioned example of heart attack, unequivocally warrants
their use in genetic tests. 
The second main theme of concern raised by commen-
tators relates to the capacity of consumers to understand
and cope with disease risk estimates from tests.
8,9,12-14
Underlying these concerns is a somewhat paternalistic
and patronizing view that information about disease risk
is dangerous to the general public unless mediated in
person by medical experts. Among the alleged dangers
to the public are anxieties from overinterpreting risk
estimates, which could lead to increased demands on
health care providers and unnecessary medical proce-
dures. We are not aware of any evidence that has been
reported in support of this view, but there is at least
some indirect evidence against it.
26
However, even if such information were to provoke anx-
iety, the right of regulators or medical experts to prevent
access to it is questionable. Consider the following anal-
ogy of a hypothetical company that provides individuals
with reliable estimates of their risk of being mugged,
murdered, run over, or burgled based on their age, sex,
and address. There is no question that someone living in
a rough inner-city area with limited economic means
would have considerably greater risk on all counts than
people living in more affluent areas. Would this be a
legitimate reason for preventing individuals from seek-
ing such potentially anxiety-provoking information? 
Another issue raised by commentators is that of clinical
utility,
10,13 that is, the extent to which knowledge of
increased risk can reduce the burden of a disease
through prevention or treatment. Although frequently
raised in discussions of DTC genetic tests, this issue is
really only relevant within the scope of health care pro-
vision (for example in the case of Huntington’s disease).
Thus, for DTC genetic tests, clinical utility is a secondary
issue when balanced against peoples’ right to seek infor-
mation about themselves at their own cost. Given that
such tests are in accordance with the accepted scientific
literature and adhere to consumer laws (ie, that they
deliver what their providers promise), then it is hard to
see how regulators could prevent the public from buy-
ing them. 
The challenge for providers of 
DTC genetic tests
In our opinion, the key to the success of DTC genetic
tests for consumers, the companies that provide them,
and regulators, is clarity and transparency. Whether tests
report disease risk estimates, ancestry analyses, or eval-
uation of genealogical relationships, the information
used to motivate consumers to buy tests and then
explain the results should be as clear and accurate as
possible. In particular, the probabilistic rather than
deterministic nature of disease risk estimation must be
unambiguous and comprehensible to the layman (and to
medical experts). A key task is also to use the scientific
literature in an accurate and responsible manner, for
example by including only sequence variants with asso-
ciations to disease that have been robustly replicated.
Translational research
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parency, ie, by providing information about all the
sequence variants used and the parameter values for risk
models and their sources in the scientific literature. Most
of the current providers of DTC personal genome scans
have followed this approach, to a greater or lesser
extent. 
If such basic ground rules are adhered to, we believe that
DTC genetic tests can provide considerable value to the
general public, in particular while tests based on disease-
associated variants discovered through GWAS are not
available through health care providers. From a public
health perspective, there is real preventative value to be
gained from making people aware of their health and
the risks posed to it. It is true that many of the lifestyle
changes recommended for prevention through the appli-
cation of DTC genetic tests could benefit many individ-
uals, regardless of whether they take such tests.
However, as most health care providers know, people
are generally reluctant to change their lifestyle, even in
the face of stern advice from medical experts. We would
argue that when genetic risk factors are added on to con-
ventional lifestyle risk factors in motivating people to
take preventative measures, the outcome provides a
greater impetus to act. Of course, from the perspective
of personal autonomy, even if people choose to disre-
gard advice about disease prevention, their right to seek
information about genetic risk should prevail. 
It is also important to highlight the educational nature
of the Web sites of many companies that offer DTC
genetic tests. They usually contain detailed information
on hundreds of Web pages about diseases, ancestry, and
genetic discoveries and methods that are used to provide
results. This information is typically available to anyone
through various front-end Web pages, where potential
buyers can explore the kind of information they would
receive as customers. Anyone can therefore learn a great
deal about diseases, ancestry, and genetics without pay-
ing for a test. Whether the decision to buy a test is moti-
vated by health concerns, recreational curiosity, or van-
ity, the consumer is almost certain to gain not only an
increased understanding of genetics in general, but also
what the recent wave of discoveries in the human genet-
ics of disease and ancestry mean for them personally.
Conclusion
We believe that DTC genetic tests play a key transla-
tional role for the science of genetics, democratizing and
disseminating privileged knowledge to the public. No
matter how clichéd it sounds, knowledge is power. While
some medical experts may complain about patients
armed with results from DTC genetic tests or informa-
tion about disease symptoms from the internet,
13 we
believe that a knowledgeable public is an empowered
public.  ❏
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Pasado, presente y futuro de las pruebas
genéticas dirigidas a los usuarios
Los avances tecnológicos en el campo de la gené-
tica humana han producido una ola de descubri-
mientos de variantes de la secuencia común del
ADN que están asociadas con un riesgo de enfer-
medades comunes y complejas, como el ataque car-
díaco, que dan cuenta de un porcentaje significa-
tivo de morbilidad, mortalidad y costos de salud en
la mayoría de las poblaciones actuales. El poder pre-
dictor en conjunto de estas variantes de la secuen-
cia puede ser considerable, debido a la alta inci-
dencia de estas enfermedades y al reducido número
de asociaciones que se han descubierto. Los prove-
edores de atención de salud han utilizado lenta-
mente este conocimiento para la medicina preven-
tiva. Sin embargo, algunas empresas han asumido
un papel translacional al ofrecer pruebas genéticas
basadas en estos descubrimientos dirigidas a los
usuarios. En este artículo se revisa tanto el estado
actual y las perspectivas futuras de tales pruebas
genéticas, como a los científicos involucrados en el
descubrimiento de las asociaciones de enfermeda-
des y en el desarrollo de las pruebas genéticas.  
Les tests génétiques en vente libre : 
passé, présent, futur
Les avancées technologiques en génétique humaine
ont permis une série de découvertes de variants fré-
quents de séquence d’ADN associés à un risque de
maladies complexes courantes, comme la crise car-
diaque, responsables d’une morbi-mortalité et de
coûts liés à la santé très importants chez la plupart
de nos contemporains. La puissance prédictive glo-
bale de ces variants génétiques peut être considé-
rable en raison de la fréquence élevée de ces mala-
dies et du seul nombre d’associations découvertes.
Les acteurs du système de santé ont mis du temps à
utiliser ces données en médecine préventive.
Plusieurs laboratoires ont néanmoins accepté de
servir d’intermédiaire en proposant directement au
grand public des tests génétiques basés sur ces
découvertes. En tant que scientifiques impliqués à
la fois dans la découverte d’associations de mala-
dies et dans le développement de tests génétiques,
nous analysons dans cet article l’état actuel et le
devenir de tels tests.
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